Prof. Pan has pioneered the clinical translation of allogeneic CD7-targeted CAR-T cells derived from HLA-matched donors, establishing a groundbreaking strategy for r/r T-ALL. Furthermore, to address antigen escape—a primary mechanism of treatment failure—the applicant developed a dual-epitope CD5 CAR-T regimen as a salvage therapy post-CD7 CAR-T failure, and a sequential CD19/CD22 CAR-T strategy that significantly improved long-term outcomes in r/r B-ALL. These seminal works, published in high-impact journals including Nature Medicine, The Lancet Oncology, Journal of Clinical Oncology and Blood, have been cited extensively, incorporated into six domestic and international clinical guidelines.

MD, PhD, Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2018-2021

Tenure-track Associate Professor, Chinese Academy of Medical Sciences and Peking Union Medical College,2026-

Chief Physician, Institute of Hematology and Blood Diseases Hospital,2026-

PRINCIPAL HONORS, AWARDS:

2021    Top 10 Research Advances in Hematology in China

2024    Top 10 Research Advances in Hematology in China

SELECTED PUBLICATIONS:

1. Pan J, et al.. Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial. Nat Med. 2025;31(1):126-136.

2. Pan J, et al.. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study, Lancet Oncology, 2023, 24(11): 1229-1241.

3. Pan J, et al..Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial, JCO, 2021, 39(30): 3340-3351.